Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The companyâ€™s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurexâ€™s platform of novel NMDAR modulators.
Funding Rounds (4) - $82.1MUpdate
Genesys Capital is focused on building companies in the high-growth sectors of healthcare and...
Early stage healthcare
Adams Street Partners is a private equity investor that has been investing since 1972. They...
Savitr Capital, LLC (“Savitr”) is an Investment Manager. They focus on investing in renewable and...
American Healthcare Company
TVI's mission is to identify, help create and support the development of therapeutic...
1801 Maple Avenue
Evanston, IL 60201